pp-246 Capsules
Dossier type
CTD
Dossier status
Under development
Country of origin
Canada
GMP approvals
Canada
Comments
Indication: Focal-onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) / Clinical stage: Phase 3 / Modality: Small molecule Kv7 potassium channel opener / Mechanism & Target: Kv7 channel activation reducing neuronal excitability / Route & form: Oral / Differentiation: Multiple Phase 3 epilepsy trials; X-TOLE2 topline H1 March 2026; lead indication focal-onset seizures
Manufacturer #39445
| Clinical-stage biopharmaceutical company focused on ion channel biology for neurology and CNS. Develops selective potassium and sodium channel modulators for epilepsy and neurological disorders. Advances lead Phase 3 candidates through global pivotal clinical trials. |
None